Cargando…
A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19
A literature review on new-onset autoimmune connective tissue diseases (ACTDs) following COVID-19 is lacking. We evaluated potential associations between COVID-19 and the development of new-onset ACTDs. The “population” was adults with disease terms for ACTDs, including systemic lupus erythematosus...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927056/ https://www.ncbi.nlm.nih.gov/pubmed/36786873 http://dx.doi.org/10.1007/s00296-023-05283-9 |
_version_ | 1784888405061009408 |
---|---|
author | Kouranloo, Koushan Dey, Mrinalini Elwell, Helen Nune, Arvind |
author_facet | Kouranloo, Koushan Dey, Mrinalini Elwell, Helen Nune, Arvind |
author_sort | Kouranloo, Koushan |
collection | PubMed |
description | A literature review on new-onset autoimmune connective tissue diseases (ACTDs) following COVID-19 is lacking. We evaluated potential associations between COVID-19 and the development of new-onset ACTDs. The “population” was adults with disease terms for ACTDs, including systemic lupus erythematosus (SLE), Sjogren’s syndrome, systemic sclerosis (SSc), idiopathic inflammatory myositis (IIM), anti-synthetase syndrome, mixed CTD and undifferentiated CTD, and “intervention” as COVID-19 and related terms. Databases were searched for English-language articles published until September 2022. We identified 2236 articles with 28 ultimately included. Of the 28 included patients, 64.3% were female, with a mean age was 51.1 years. The USA reported the most cases (9/28). ACTD diagnoses comprised: 11 (39.3%) IIM (including four dermatomyositis); 7 (25%) SLE; four (14.3%) anti-synthetase syndrome; four (14.3%) SSc; two (7.1%) other ACTD (one lupus/MCTD overlap). Of eight, four (14.3%) patients (including that with lupus/MCTD) had lupus nephritis. The average time from COVID-19 to ACTD diagnosis was 23.7 days. A third of patients were admitted to critical care, one for treatment of haemophagocytic lymphohistiocytosis in SLE (14 sessions of plasmapheresis, rituximab and intravenous corticosteroids) and nine due to COVID-19. 80% of patients went into remission of ACTD following treatment, while three (10%) patients died—one due to macrophage activation syndrome with anti-synthetase syndrome and two from unreported causes. Our results suggest a potential association between COVID-19 and new-onset ACTDs, notably in young females, reflecting more comprehensive CTD epidemiology. The most common diagnosis in our cohort was IIM. The aetiology and mechanisms by which ACTDs emerge following COVID-19 remain unknown and require further research. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00296-023-05283-9. |
format | Online Article Text |
id | pubmed-9927056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-99270562023-02-15 A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19 Kouranloo, Koushan Dey, Mrinalini Elwell, Helen Nune, Arvind Rheumatol Int Systematic Review A literature review on new-onset autoimmune connective tissue diseases (ACTDs) following COVID-19 is lacking. We evaluated potential associations between COVID-19 and the development of new-onset ACTDs. The “population” was adults with disease terms for ACTDs, including systemic lupus erythematosus (SLE), Sjogren’s syndrome, systemic sclerosis (SSc), idiopathic inflammatory myositis (IIM), anti-synthetase syndrome, mixed CTD and undifferentiated CTD, and “intervention” as COVID-19 and related terms. Databases were searched for English-language articles published until September 2022. We identified 2236 articles with 28 ultimately included. Of the 28 included patients, 64.3% were female, with a mean age was 51.1 years. The USA reported the most cases (9/28). ACTD diagnoses comprised: 11 (39.3%) IIM (including four dermatomyositis); 7 (25%) SLE; four (14.3%) anti-synthetase syndrome; four (14.3%) SSc; two (7.1%) other ACTD (one lupus/MCTD overlap). Of eight, four (14.3%) patients (including that with lupus/MCTD) had lupus nephritis. The average time from COVID-19 to ACTD diagnosis was 23.7 days. A third of patients were admitted to critical care, one for treatment of haemophagocytic lymphohistiocytosis in SLE (14 sessions of plasmapheresis, rituximab and intravenous corticosteroids) and nine due to COVID-19. 80% of patients went into remission of ACTD following treatment, while three (10%) patients died—one due to macrophage activation syndrome with anti-synthetase syndrome and two from unreported causes. Our results suggest a potential association between COVID-19 and new-onset ACTDs, notably in young females, reflecting more comprehensive CTD epidemiology. The most common diagnosis in our cohort was IIM. The aetiology and mechanisms by which ACTDs emerge following COVID-19 remain unknown and require further research. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00296-023-05283-9. Springer Berlin Heidelberg 2023-02-14 2023 /pmc/articles/PMC9927056/ /pubmed/36786873 http://dx.doi.org/10.1007/s00296-023-05283-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Systematic Review Kouranloo, Koushan Dey, Mrinalini Elwell, Helen Nune, Arvind A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19 |
title | A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19 |
title_full | A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19 |
title_fullStr | A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19 |
title_full_unstemmed | A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19 |
title_short | A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19 |
title_sort | systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after covid-19 |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927056/ https://www.ncbi.nlm.nih.gov/pubmed/36786873 http://dx.doi.org/10.1007/s00296-023-05283-9 |
work_keys_str_mv | AT kouranlookoushan asystematicreviewoftheincidencemanagementandprognosisofnewonsetautoimmuneconnectivetissuediseasesaftercovid19 AT deymrinalini asystematicreviewoftheincidencemanagementandprognosisofnewonsetautoimmuneconnectivetissuediseasesaftercovid19 AT elwellhelen asystematicreviewoftheincidencemanagementandprognosisofnewonsetautoimmuneconnectivetissuediseasesaftercovid19 AT nunearvind asystematicreviewoftheincidencemanagementandprognosisofnewonsetautoimmuneconnectivetissuediseasesaftercovid19 AT kouranlookoushan systematicreviewoftheincidencemanagementandprognosisofnewonsetautoimmuneconnectivetissuediseasesaftercovid19 AT deymrinalini systematicreviewoftheincidencemanagementandprognosisofnewonsetautoimmuneconnectivetissuediseasesaftercovid19 AT elwellhelen systematicreviewoftheincidencemanagementandprognosisofnewonsetautoimmuneconnectivetissuediseasesaftercovid19 AT nunearvind systematicreviewoftheincidencemanagementandprognosisofnewonsetautoimmuneconnectivetissuediseasesaftercovid19 |